The Institute of NeuroPhysiopathology (INP) is a training and research centre of excellence that combines basic and translational research to study neural cell organisation, function and interaction, the molecular and cellular bases of major brain diseases, and to develop innovative cellular and molecular therapeutic strategies.
The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.
We are pleased to announce that our team has obtained a FRM "2024 prematuration" grant for a project in collaboration with BBB team and Vect-Horus.
The funding will start 1st of November for one year and will allow us to pursue our scientific research on MT5-MMP and its role in Alzheimer disease using in this particular project vectorised mimetic peptides as a potential therapeutical approach.
Maud Gratuze (SynapTau team) has been invited to the SNE 2024 in Nice to give a presentation titled "Unveiling the Brain's Chubby Secrets: Disrupted Cholesterol and Lipid Metabolism in Alzheimer's Disease" at a symposium on Alzheimer's disease.
A new article from the GlioME Team has just been published in Cell Death and Disease: SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment.
Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.
Three presentations at the ESMO Congress 2024 (Barcelona, 13–17 September) reported on therapies designed to stimulate or boost the body’s antitumour immune response in the management of aggressive, high-grade gliomas, which typically carry a poor prognosis.
Emeline Tabouret from GlioME Team discussed these data during the proffered paper session – CNS tumours reported here.
Maud, Chiara, and Matthew (SynapTau team) are happy to announce the award of an ERC Starting Grant for the team, with the project set to begin in January 2025. The ERC project "SynApoE" aims to characterize how ApoE4 controls synaptic degeneration in Alzheimer's disease.
We invite you to celebrate this great news on September 23rd, during Maud's HDR celebration.
We look forward to sharing this moment with you!
We’re over the moon to see our latest work with Stéphane Vassilopoulos and his team published in Science. Check out how we reveal the unique architecture of clathrin-coated pits and endocytosis at the axon initial segment!
Comme chaque année les équipes 8, 9 et 10 de l’INP ont participé au Séminaire Annuel du Canceropôle qui se tenait au Palais des Congrès de Saint-Raphaël les 4 et 5 juillet 2024.
The NeuroCyto lab is looking to hire a postdoctoral fellow for an exciting project at the interface of microscopy and neuronal cell biology.
Deadline for application: January 15th, 2023. Starting date (flexible): April 2023.
About the position and project
We are pleased to announce that our team has obtained a FRM "2024 prematuration" grant for a project in collaboration with BBB team and Vect-Horus.
The funding will start 1st of November for one year and will allow us to pursue our scientific research on MT5-MMP and its role in Alzheimer disease using in this particular project vectorised mimetic peptides as a potential therapeutical approach.
Maud Gratuze (SynapTau team) has been invited to the SNE 2024 in Nice to give a presentation titled "Unveiling the Brain's Chubby Secrets: Disrupted Cholesterol and Lipid Metabolism in Alzheimer's Disease" at a symposium on Alzheimer's disease.
A new article from the GlioME Team has just been published in Cell Death and Disease: SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment.
Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.
Three presentations at the ESMO Congress 2024 (Barcelona, 13–17 September) reported on therapies designed to stimulate or boost the body’s antitumour immune response in the management of aggressive, high-grade gliomas, which typically carry a poor prognosis.
Emeline Tabouret from GlioME Team discussed these data during the proffered paper session – CNS tumours reported here.
The NeuroCyto lab is looking to hire a postdoctoral fellow for an exciting project on novel mechanisms of microtubule turnover in neurons, in collaboration with collaboration with the lab of Manuel Théry and Laurent Blanchoin (CytoMorpho lab, ESPCI, Paris).
Maud, Chiara, and Matthew (SynapTau team) are happy to announce the award of an ERC Starting Grant for the team, with the project set to begin in January 2025. The ERC project "SynApoE" aims to characterize how ApoE4 controls synaptic degeneration in Alzheimer's disease.
We invite you to celebrate this great news on September 23rd, during Maud's HDR celebration.
We look forward to sharing this moment with you!
We’re over the moon to see our latest work with Stéphane Vassilopoulos and his team published in Science. Check out how we reveal the unique architecture of clathrin-coated pits and endocytosis at the axon initial segment!
Comme chaque année les équipes 8, 9 et 10 de l’INP ont participé au Séminaire Annuel du Canceropôle qui se tenait au Palais des Congrès de Saint-Raphaël les 4 et 5 juillet 2024.
titre de la présentation : First results from the EPIsoDE trial, a phase IIb study to assess efficacy and safety of psilocybin for treatment-resistant depression
un court abstract:
Psilocybin is being extensively studied for treating depressive disorders, with promising results. The German EPIsoDE trial
(EudraCT: 2019-003984-24; NCT04670081) is a randomized, double-blind, placebo-controlled study comparing high-dose (25 mg)
and low-dose (5 mg) psilocybin with an active placebo (100 mg nicotinamide) in patients with treatment-resistant depression (TRD).
Between July 2021 and February 2024, 144 patients were treated at two sites (Charité Berlin and CIMH Mannheim).
Participants were assigned to one of four treatment arms, receiving one or two doses of psilocybin, with all patients receiving
at least one high dose for ethical reasons. This talk will present the study’s rationale and early results, along with insights
from treating this vulnerable TRD population. Challenges and lessons from the trial will be discussed, with implications for future
research and clinical practice.
Seminaire interne ouvert à l'INP
Title : From the identification of a molecular signature of multiple sclerosis to the validation of the pro-differentiating and remyelinating effect of lumican
Aix Marseille Université | All rights reserved - Legal notice
